Every Form 4 that Dexcom Inc (DXCM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DXCM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DXCM filings page.
DEXCOM INC (DXCM) executive Sadie Stern, EVP Chief People & Culture Officer, reported selling 2,565 shares of Common Stock on August 27, 2026 at $88.37 per share in an open-market transaction. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on May 28, 2026. After this sale, Stern holds 126,043 shares directly, including 71,903 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029.
DEXCOM INC (DXCM) reported that President, CEO, and Director Jacob Steven Leach had 1,451 shares of common stock withheld on 2026-08-22 to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units; this is explicitly stated not to be a market sale. After this withholding, he holds 418,908 direct shares, including 142,836 unvested restricted stock units with grants from March 8, 2024, 2025, and 2026 that vest through March 8, 2029. He also has 47,296 shares held indirectly through the Gregg Family Grandchildren's Trust, with his spouse serving as trustee.
DEXCOM INC (DXCM) reported that EVP and Chief Financial Officer Jereme M. Sylvain had 1,451 shares of common stock withheld on 2026-08-22 to satisfy tax withholding and remittance obligations tied to the net settlement of restricted stock units; this was not an open-market sale. After this withholding, he holds 150,390 shares directly, including 87,094 unvested restricted stock units with grants on March 8, 2026, 2025 and 2024 that vest through dates extending to March 8, 2029.
DEXCOM INC (DXCM) reported that executive officer Michael Jon Brown had 1,451 shares of common stock withheld on August 22, 2026 to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units. This was not an open-market sale. After this withholding, Brown directly holds 101,502 shares of Dexcom common stock, including 71,903 unvested restricted stock units that vest in tranches from March 8, 2024 through March 8, 2029.
DEXCOM INC (DXCM) reported that executive officer Sadie Stern, EVP Chief People & Culture Officer, had 1,451 shares of common stock withheld on August 22, 2026 to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units; this was not an open-market sale. After this withholding, Stern directly holds 128,608 shares of Dexcom common stock, including 71,903 unvested restricted stock units that vest on various schedules through March 8, 2029.
DEXCOM INC (DXCM) Executive Chair Kevin R. Sayer reported open-market sales of a total of 26,756 shares of common stock on August 20, 2026, in three transactions at weighted average prices of about $89.71, $90.78, and $91.41. These sales were made under a Rule 10b5-1 trading plan adopted on February 18, 2026. Sayer continues to hold equity awards, including 106,972 unvested restricted stock units with grants from 2024–2026 that vest through dates in 2027 and 2028.
DEXCOM INC executive Michael Jon Brown, EVP Chief Legal Compliance Officer, reported selling 1,700 shares of common stock on August 14, 2026 at $91.93 per share in an open-market transaction under a pre-arranged Rule 10b5-1 Plan. Following this sale, he directly holds 102,953 shares, including 74,753 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029.
DEXCOM INC director Nicholas Augustinos reported a bona fide gift of 1,075 shares of Dexcom common stock on 2026-08-12. The donated shares were held indirectly through the Kirschner/Augustinos Revocable Trust and were contributed to a charitable donor advised fund, leaving 37,382 shares held by the trust. Separately, Augustinos holds 5,575 unvested restricted stock units granted on May 28, 2026, which will vest on the earlier of the one-year anniversary of that grant or DexCom, Inc.'s 2027 Annual Meeting of Stockholders.
DexCom Inc. director Bridgette P. Heller reported an open-market sale of 1,012 shares of Common Stock on August 12, 2026 at $88.29 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on August 14, 2025. After this transaction, she directly holds 29,570 shares, including 5,575 unvested restricted stock units that were granted on May 28, 2026 and will vest on the earlier of the one-year anniversary of the grant date or DexCom’s 2027 Annual Meeting of Stockholders.
A family trust associated with DexCom Inc. director Mark G. Foletta sold 4,000 shares of common stock in two indirect open-market transactions: 2,000 shares at $80.00 on July 31, 2026 and 2,000 shares at $85.32 on August 3, 2026, pursuant to a pre‑arranged 10b5‑1 Plan adopted by the Foletta Family Trust on March 13, 2026.
Foletta also directly holds 6,331 unvested restricted stock units granted on May 28, 2026, scheduled to vest on the earlier of the one‑year grant anniversary or DexCom’s 2027 annual meeting of stockholders.
Dexcom Inc Executive Chair Kevin R. Sayer sold 26,756 shares of common stock on July 20, 2026 at a weighted average price of $76.3193 per share, in multiple trades between $75.80 and $76.62. The sale was made under a Rule 10b5-1 trading plan adopted on February 18, 2026 for orderly dispositions of his holdings. Following this sale, he directly holds 328,970 shares, including 106,972 unvested restricted stock units that were granted in 2024–2026 and will vest through 2028.
DEXCOM INC executive Michael Jon Brown, EVP Chief Legal Compliance Officer, reported an open-market sale of 1,700 shares of Dexcom common stock on July 15, 2026 at an average price of $74.42 per share, executed under a 10b5-1 plan adopted on November 26, 2025. Following this transaction, he holds 104,653 shares in total, including 74,753 unvested restricted stock units scheduled to vest in several grants through March 8, 2029.
Dexcom Inc. Executive Chair Kevin R. Sayer sold 26,756 shares of common stock in an open-market transaction at $72.00 per share. The sale was executed under a Rule 10b5-1 trading plan that Sayer adopted on February 18, 2026 to allow orderly dispositions of his holdings.
After the transaction, Sayer directly owns 355,726 Dexcom shares, which include 106,972 unvested restricted stock units scheduled to vest in tranches through March 8, 2028. The filing shows he retains a substantial equity position following this planned sale.
DexCom Inc. executive Michael Jon Brown, EVP and Chief Legal Compliance Officer, reported an open-market sale of 1,700 shares of common stock at $75.55 per share on June 15, 2026. After the sale, he directly holds 106,353 shares, including 74,753 unvested restricted stock units that vest over multiple dates through March 8, 2029. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, indicating it was scheduled in advance as part of an orderly disposition program.
Dexcom Inc. director Mark G. Foletta reported indirect stock sales executed by The Foletta Family Trust under a pre-arranged Rule 10b5-1 trading plan. On June 15, 2026, the trust sold a total of 4,000 Dexcom common shares in open-market transactions at weighted average prices around $74 per share.
The filing shows two sale blocks: 3,801 shares at a weighted average price of $74.0991 and 199 shares at a weighted average price of $74.8187. Following the transactions, Foletta also reports holding 6,331 Dexcom shares directly.
Dexcom Inc. executive Jon Coleman reported open-market sales of company stock under a pre-arranged trading plan. On June 3, 2026, he sold 4,912 shares of common stock at $73.00 per share. On June 4, 2026, he sold an additional 4,911 shares at $74.13 per share.
These transactions, totaling 9,823 shares, were executed pursuant to a Rule 10b5-1 Plan adopted on March 4, 2026, which is designed to allow orderly, pre-scheduled dispositions. After these sales, Coleman directly held 95,450 shares of Dexcom common stock. A related disclosure notes that this number includes 95,450 unvested restricted stock units, consisting of 43,897 units granted March 8, 2026 vesting through March 8, 2029, and 51,553 units granted May 22, 2025 vesting through May 22, 2029. The filing shows no derivative positions remaining.
ALTMAN STEVEN R reported acquisition or exercise transactions in this Form 4 filing.
DexCom director Steven R. Altman received a grant of 5,565 restricted stock units of DexCom common stock. The award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or DexCom's 2027 Annual Meeting of Stockholders. Each unit represents a contingent right to receive one share of common stock upon settlement. Following the grant, Altman holds 5,565 shares directly from this award and 63,667 shares indirectly through the Altman Family Trust, where he serves as trustee.
Malady Kyle reported acquisition or exercise transactions in this Form 4 filing.
DexCom Inc. director Kyle Malady received an equity award in the form of restricted stock units. The Form 4 reports a grant of 5,575 shares of Common Stock at no cash cost as a compensation-related award, bringing his direct holdings to 28,242 shares.
The award is structured as RSUs, each representing a contingent right to receive one DexCom share upon settlement. According to the terms, 100% of the RSU award will vest on the earlier of one year after the May 28, 2026 grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders.
AUGUSTINOS NICHOLAS reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Nicholas Augustinos reported a new equity award and updated holdings. He received a grant of 5,575 restricted stock units (RSUs) on May 28, 2026, with each RSU representing one share of Dexcom common stock upon settlement.
The RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom's 2027 Annual Meeting of Stockholders. Following this award, he holds 5,575 shares directly and 38,457 shares indirectly through the Kirschner/Augustinos Revocable Trust, where he serves as a trustee.
FOLETTA MARK G reported acquisition or exercise transactions in this Form 4 filing.
Dexcom director Mark G. Foletta received a grant of 6,331 restricted stock units (RSUs) of Dexcom common stock. The award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom's 2027 Annual Meeting of Stockholders. Each RSU represents a contingent right to receive one share of common stock upon settlement. After the grant, Foletta holds 6,331 shares directly and 56,852 shares indirectly through The Foletta Family Trust DTD 1/30/2015, where he serves as trustee.
Heller Bridgette P reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Bridgette P. Heller received an equity award of 5,575 restricted stock units (RSUs) of common stock. The RSU grant was made on May 28, 2026 at no cash cost to her and is compensation-related, not an open-market purchase. The RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 Annual Meeting of Stockholders. After this award, Heller directly holds 30,582 shares of Dexcom common stock.
Osterloh Albert Frederick IV reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Albert Frederick Osterloh IV received an equity grant of 1,630 restricted stock units (RSUs) of Dexcom common stock on May 28, 2026. The award was granted at no cash cost as part of compensation, not through an open-market purchase.
All 1,630 RSUs will vest on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 Annual Meeting of Stockholders. After this grant, Osterloh holds 8,691 unvested RSUs in total, including 7,061 RSUs granted on February 26, 2026 that are scheduled to vest through February 26, 2029.
Driscoll Rimma reported acquisition or exercise transactions in this Form 4 filing.
DexCom Inc. director Rimma Driscoll received a compensation-related stock award. She was granted 5,605 shares of DexCom common stock in the form of restricted stock units at a price of $0.00 per share.
The RSU award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders. Each restricted stock unit represents a contingent right to receive one DexCom common share upon settlement.
After this award, Driscoll directly holds 17,319 DexCom shares, which include 6,941 unvested restricted stock units. Of these unvested units, 5,605 were granted on May 28, 2026 and 1,336 were granted on August 24, 2023, scheduled to vest through August 24, 2026.
Ashley Euan A. reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Euan A. Ashley received an equity grant of 5,565 restricted stock units (RSUs) on May 28, 2026. The award carries no purchase price and is structured as stock-based compensation, not an open-market share purchase.
According to the terms, 100% of this RSU award will vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. After this grant, Ashley holds 12,731 unvested RSUs in total, including 7,166 RSUs granted on October 24, 2025 that are scheduled to vest in tranches through October 24, 2028.
Collins Richard Alexander reported acquisition or exercise transactions in this Form 4 filing.
DexCom director Richard Alexander Collins reported a new equity award and his current holdings. He received a grant of 5,605 shares of DexCom common stock in the form of restricted stock units at a stated price of $0.00 per share. The RSU award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders. Each restricted stock unit represents a contingent right to receive one share of DexCom common stock upon settlement. Collins also reported indirect ownership of 40,162 DexCom common shares held by the Richard A. Collins Revocable Trust, for which he serves as trustee.
GALA RENEE D reported acquisition or exercise transactions in this Form 4 filing.
Dexcom director Renee D. Gala reported an equity grant of company stock. On May 28, 2026, she received 5,605 shares of Dexcom common stock in the form of restricted stock units (RSUs), a stock-based compensation award with no cash purchase price.
After this grant, Gala’s reported direct holdings total 12,486 shares of common stock, including 9,418 unvested RSUs. Of these unvested RSUs, 5,605 were granted on May 28, 2026 and will vest on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 Annual Meeting of Stockholders. The remaining 3,813 RSUs were granted on March 6, 2025 and are scheduled to vest through March 6, 2028.
Dexcom Inc. President, CEO, and Director Jacob Steven Leach reported a tax-related share withholding and updated holdings. On this Form 4, 1,451 shares of common stock were withheld at $71.90 per share to satisfy tax obligations tied to net settlement of restricted stock units, and a footnote states this does not represent a sale by him.
After this withholding, Leach directly owned 420,359 Dexcom shares. A separate entry shows 47,296 shares held indirectly as family holdings through the Gregg Family Grandchildren's Trust, where his spouse serves as a trustee. Footnotes also note 145,686 unvested restricted stock units scheduled to vest between March 8, 2027 and March 8, 2029.
Dexcom executive Michael Jon Brown reported a routine tax-related share withholding tied to restricted stock units. On this Form 4, 1,451 shares of common stock were withheld at $71.90 per share to satisfy tax obligations from the net settlement of vested RSUs, and the footnote clarifies this was not an open-market sale.
After the withholding, Brown directly holds 108,053 Dexcom shares, which include 74,753 unvested restricted stock units scheduled to vest in tranches through March 8, 2029.
Dexcom EVP and Chief Financial Officer Sylvain Jereme M reported a routine tax-related share withholding. On May 22, 2026, 1,451 shares of Dexcom common stock were withheld at $71.90 per share to cover tax obligations tied to restricted stock unit settlement, and the footnote clarifies this does not represent a sale.
After this withholding, he directly holds 151,841 shares of common stock, which includes 89,944 unvested restricted stock units. These RSUs were granted in multiple awards between March 8, 2024 and March 8, 2026 and are scheduled to vest through March 8, 2029, indicating a significant ongoing equity-based compensation position.
Dexcom EVP Chief People & Culture Officer Sadie Stern reported a routine tax-withholding event related to equity compensation. On the reported date, 1,451 shares of Dexcom common stock were withheld at $71.90 per share to cover tax obligations from the net settlement of restricted stock units.
The footnotes clarify this was not an open-market sale, but shares retained by the company to satisfy required tax withholding and remittance. After this withholding, Stern directly held 130,059 Dexcom shares, including 74,753 unvested restricted stock units that vest on various schedules through March 8, 2029.
Dexcom EVP Jon Coleman had shares withheld to cover taxes on stock awards. On this Form 4, 7,362 shares of Dexcom common stock were surrendered at $71.90 per share to satisfy tax withholding obligations from the net settlement of restricted stock units, and this is explicitly stated not to be a sale.
After this tax withholding, Coleman directly holds 105,273 shares of Dexcom, including 95,450 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029 and May 22, 2029. This filing reflects routine compensation-related tax treatment rather than an open‑market trade.
Dexcom Executive Chair Kevin R. Sayer reported an open-market sale of 26,759 shares of Dexcom common stock on May 21, 2026 at $72.00 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 18, 2026, which is designed to allow the orderly disposition of his shares over time.
Following this sale, Sayer directly owns 382,482 Dexcom shares, which include 106,972 unvested restricted stock units. These unvested units stem from grants made on March 8, 2024, 2025, and 2026, each scheduled to vest gradually through dates between 2027 and 2028.
Dexcom Inc. executive vice president and chief legal officer Michael Jon Brown sold 1,700 shares of common stock on May 15, 2026 in an open-market trade at $59.91 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025. After the transaction, he holds 109,504 shares directly, including 77,603 unvested RSUs that are scheduled to vest in tranches through March 8, 2029.
Dexcom Inc. director Bridgette P. Heller reported an open-market sale of 1,012 shares of common stock at $60.01 per share. After the transaction, she directly holds 25,007 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, which provides for orderly share dispositions.
DEXCOM INC director Nicholas Augustinos reported non-cash share transfers on Form 4. He recorded two bona fide gift transactions involving a total of 10,092 shares of common stock, tied to the vesting of previously awarded restricted stock units and movement of shares into the Kirschner/Augustinos Revocable Trust.
Following these transactions, Augustinos holds 38,457 shares indirectly through the revocable trust, with no shares reported as held directly. No open-market purchases or sales were reported, and the transactions involved a price of $0.00 per share.
Dexcom Inc. director Richard Alexander Collins reported internal share transfers involving 10,148 shares of common stock. On 2026-05-08, 5,074 shares moved from his direct ownership to the Richard A. Collins Revocable Trust, with both legs reported as bona fide gifts. After these entries, he holds 40,162 Dexcom shares indirectly through the trust and no shares directly.
Dexcom Inc. director Mark G. Foletta reported non-market transfers of Dexcom common stock classified as bona fide gifts. On 2026-05-08, he disposed of a total of 11,462 shares at a stated price of $0.00 per share, reflecting that no cash was received.
One transaction moved 5,731 directly held shares to the Mark G. and Mary E. Foletta Family Trust, and a second transaction reduced his remaining directly held shares by another 5,731. After these transfers, 56,852 shares are held indirectly through the family trust, while his direct holdings are reported as zero.
Dexcom director Steven R. Altman reported a bona fide gift of 10,074 shares of Dexcom common stock. The filing shows two gift transactions of 5,037 shares each on common stock. Following these transactions, 63,667 shares are held indirectly through the Altman Family Trust, where Altman serves as trustee, and his direct holdings in these reported shares are now zero.
Dexcom Inc.’s EVP and Chief Legal Officer Michael Jon Brown sold 1,700 shares of common stock in an open-market transaction. The shares were sold at $63.04 each under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025.
Following this sale, Brown directly owns 111,204 Dexcom shares77,603 unvested RSUs, with grants made on March 8, 2026, March 8, 2025, and March 8, 2024 that are scheduled to vest through March 8, 2029.
Dexcom Inc. executive Michael Jon Brown, EVP and Chief Legal Officer, reported an open-market sale of 1,700 shares of common stock at $64.85 per share. The transaction occurred on March 16, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025.
After this sale, Brown directly holds 112,904 Dexcom shares. This figure includes 77,603 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029, reflecting a substantial continuing equity stake aligned with the company’s long-term performance.
DexCom Inc. Executive Chair Kevin R. Sayer reported routine equity compensation activity. He received a grant of 32,749 restricted stock units (RSUs) of DexCom common stock on March 8, 2026. These RSUs are scheduled to vest on the one-year anniversary of the grant date.
The filing also shows 32,498 shares of common stock withheld by DexCom at $68.10 per share to satisfy tax withholding and remittance obligations related to RSU settlement, which the company states does not represent a sale by Sayer. After these transactions, he directly holds 409,241 shares, including 106,972 unvested RSUs with various vesting schedules through March 8, 2028.
Dexcom Inc. EVP and CFO Sylvain Jereme reported a compensation-related equity transaction. He received a grant of 48,774 restricted stock units (RSUs) that will vest in three equal annual installments from the March 8, 2026 grant date. On the same date, 18,950 shares of common stock at $68.10 per share were withheld by Dexcom to satisfy tax obligations from RSU settlements, which the company states does not represent a sale by him. Following these transactions, he directly owns 153,292 Dexcom shares, including 92,794 unvested RSUs with various grant dates vesting through March 8, 2029.
DexCom Inc. executive Michael Jon Brown received a new equity award and had shares withheld for taxes. On March 8, 2026, he acquired 39,019 shares of Common Stock through a grant of restricted stock units (RSUs) that vest in three equal annual installments from the grant date.
On the same date, 23,325 shares of Common Stock were withheld by DexCom at $68.10 per share to cover tax withholding and remittance obligations in connection with RSU net settlement, which the disclosure notes does not represent a sale by Brown. After these transactions, he directly holds 114,604 shares of DexCom Common Stock, and this figure includes 77,603 unvested RSUs with various vesting schedules through March 8, 2029, as well as 255 shares acquired under the company’s Amended and Restated 2015 Employee Stock Purchase Plan.
Dexcom EVP and Chief HR Officer Sadie Stern received a grant of 39,019 restricted stock units (RSUs) of Common Stock on March 8, 2026. These RSUs are scheduled to vest in three equal annual installments from the grant date, with each RSU representing a right to receive one Dexcom share.
On the same date, 17,199 shares were withheld by the company at a price of $68.10 per share to cover tax obligations related to RSU settlement; this is explicitly described as not being a sale by Stern. Following these transactions, Stern directly holds 131,510 shares of Common Stock, including 77,603 unvested RSUs with various grants vesting through March 8, 2029.
Dexcom Inc. President, CEO, and Director Jacob Steven Leach received a grant of 104,516 restricted stock units (RSUs) on March 8, 2026. These RSUs vest in three equal annual installments from the grant date, with each RSU representing a right to one share of common stock.
On the same date, 19,757 shares of common stock at $68.10 per share were withheld to cover tax obligations related to RSU net settlement, which the company notes does not represent a market sale. After these transactions, Leach directly holds 421,810 shares of common stock, including 148,536 unvested RSUs spread across multiple grant years.
In addition, 47,296 shares are held indirectly through the Gregg Family Grandchildren's Trust UAD 12/30/2010, where Leach’s spouse serves as trustee.
Coleman Jon reported acquisition or exercise transactions in this Form 4 filing.
Dexcom EVP and Chief Commercial Officer Jon Coleman received a grant of 43,897 restricted stock units (RSUs) of Dexcom common stock. These RSUs vest in three equal annual installments from the March 8, 2026 grant date. After this award, Coleman holds 112,635 unvested RSUs in total, scheduled to vest through dates extending to 2029.
Osterloh Albert Frederick IV reported acquisition or exercise transactions in this Form 4 filing.
DexCom, Inc. director Albert Frederick Osterloh IV reported receiving a grant of 7,061 restricted stock units of common stock. The award was made at a stated price of $0.00 per share and represents a contingent right to receive 7,061 DexCom common shares.
The restricted stock units vest in three equal annual installments from the grant date, meaning one‑third of the units is scheduled to vest each year over three years, subject to the grant’s terms.
DexCom director Bridgette P. Heller reported an open-market sale of 1,012 shares of Common Stock on February 12, 2026 at $68.01 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following this transaction, she beneficially owns 26,019 shares, including 5,046 unvested restricted stock units granted on May 8, 2025 that will vest on the earlier of the one-year anniversary of the grant date or DexCom, Inc.'s 2026 Annual Meeting of Stockholders.
Dexcom President and CEO Jacob Steven Leach reported equity compensation activity in the company’s common stock. On January 29, 2026, he received 8,310 shares at $0 upon vesting of previously granted performance-based restricted stock units, reflecting achieved performance goals.
To cover tax withholding on this vesting, 3,058 shares were withheld by Dexcom at $73.36 per share; this withholding is not a sale. After these transactions, Leach directly held 337,051 shares, plus 47,296 shares held indirectly through the Gregg Family Grandchildren's Trust. The direct holdings include 84,537 unvested restricted stock units with various grant and future vesting dates.
EVP and Chief HR Officer Sadie Stern reported routine equity compensation activity. On January 29, 2026, she acquired 7,123 shares of common stock at $0 upon vesting of performance-based restricted stock units granted on March 8, 2023.
The issuer withheld 2,656 shares at $73.36 solely to cover tax obligations related to this vesting, which is not a market sale by Stern. After these transactions, she directly beneficially owned 109,690 shares, including 74,450 unvested restricted stock units scheduled to vest over several dates through March 2028.